aTyr Pharma Expected to Announce Q4 2025 Earnings

Biotech company aTyr Pharma will likely release its fourth quarter 2025 financial results before the market opens on Thursday, March 12, 2026.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

aTyr Pharma, a clinical-stage biotechnology company focused on developing novel protein-based therapies, is expected to announce its Q4 2025 earnings results before the market opens on Thursday, March 12, 2026. Analysts project the company will report a loss of $0.18 per share and revenue of $0.02 million for the quarter.

Why it matters

As a publicly traded biotech company, aTyr Pharma's quarterly earnings reports are closely watched by investors and analysts to gauge the progress of its drug development pipeline and overall financial health. The company's stock price and market valuation are heavily influenced by these periodic financial updates.

The details

aTyr Pharma plans to host a conference call to discuss the Q4 2025 results on Tuesday, March 17, 2026 at 4:00 PM ET. The call will be webcast live on the company's investor relations website. Analysts expect aTyr to report a loss of $0.18 per share on revenue of $0.02 million for the quarter.

  • aTyr Pharma will release its Q4 2025 earnings before the market opens on Thursday, March 12, 2026.
  • The company will host a conference call to discuss the results on Tuesday, March 17, 2026 at 4:00 PM ET.

The players

aTyr Pharma

A clinical-stage biotechnology company focused on developing novel protein-based therapies that modulate the extracellular matrix and immune pathways. The company is headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

Investors and analysts will be closely watching aTyr Pharma's upcoming Q4 2025 earnings report to assess the company's financial performance and the progress of its drug development pipeline. The results could have a significant impact on the company's stock price and market valuation.